AIMS: To investigate relationships between glycated haemoglobin (HbA1c) and reported hypoglycaemia and risk of major adverse cardiovascular events (MACE). METHODS: The EXAMINE trial randomized 5380 @entity1 with @entity164 2 @entity6 (T2DM) and a recent @entity1187 ( @entity1187 ) event, in 49 countries, to double-blind treatment with @entity45702 or placebo in addition to standard of care. We used Cox proportional hazards models to analyse relationships among MACE, HbA1c levels and hypoglycaemic events. RESULTS: @entity1 randomized to @entity45702 achieved lower HbA1c levels than the placebo group in all baseline @entity4051 c categories without differences in hypoglycaemia rates. No systematic change was found in MACE rates according to baseline HbA1c (Pinteraction    =   0.971) or @entity4051 c category at 1   month. @entity1 in the combined treatment groups (n   =   5380) who experienced serious hypoglycaemia (n   =   34) had higher MACE rates than those who did not (35.3% vs 11.4%, adjusted hazard ratio [HR] 2.42, 95% confidence interval [CI] 1.27-4.60; P   =   .007), although the association was less strong when analysing only events after the hypoglycaemic event (adjusted HR 1.60, 95% CI 0.80, 3.20). CONCLUSIONS: There were no relationships between baseline HbA1c levels or HbA1c levels after 1   month of treatment and the risk of MACE. @entity45702 improved glycaemic control without increasing hypoglycaemia. Reported events of hypoglycaemia and serious hypoglycaemia were associated with MACE. These data underscore the safety of @entity45702 in improving glycaemic control in T2DM post- @entity1187 . Further study of hypoglycaemia as an independent risk factor for MACE in @entity1 with T2DM and coronary disease is needed.

Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in XXXX with @entity164 2 @entity6 and recent @entity1187 events: The EXAMINE trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome'] @entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity45702 :: ('MESH:C520853', 'Chemical') :: ['Alogliptin', 'alogliptin'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type']
@entity1 :: (9606,Species) :: ['patients']
